Literature DB >> 7521823

IgM and IgA antibodies generated against hepatitis C virus core antigen in patients with acute and chronic HCV infection.

S Sato1, S Fujiyama, M Tanaka, M Goto, Y Taura, S Kawano, T Sato, H Yasuo.   

Abstract

Antibody subclasses directed against the core protein (HCc) of hepatitis C virus (HCV) were measured in 27 patients with acute non-A, non-B (NANB) hepatitis, and 99 patients with chronic HCV-associated liver disease. IgM, IgA, and IgG anti-HCc responses were observed in 11 (40.7%), 7 (25.9%), and 18 (67%) patients with acute NANB hepatitis, respectively. Twenty-four (24.2%) and 40 (40.4%) patients with chronic HCV infection also had detectable IgM and IgA, respectively. IgM anti-HCc inconsistently detected acute infection, and HCV ribonucleic acid (RNA) could be detected preceding the rise in anti-HCc antibodies in five consecutive patients with acute hepatitis. IgM anti-HCc also could not distinguish acute from chronic infection and did not correlate with histologic progression. However, the form of IgA present (polymeric vs monomeric) did discriminate acute from chronic infection and the IgA anti-HCc titer correlated with histologic evidence of liver disease in patients with chronic HCV infection.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7521823     DOI: 10.1007/bf02088141

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  26 in total

1.  Two cases of accidental transmission of hepatitis C to medical staff.

Authors:  K Tsude; S Fujiyama; S Sato; S Kawano; Y Taura; K Yoshida; T Sato
Journal:  Hepatogastroenterology       Date:  1992-02

2.  Titration of antibody against hepatitis C virus core protein and its clinical utility.

Authors:  Y Taura; S Fujiyama; S Kawano; S Sato; M Goto; H Chikazawa; J Shibata; K Mizuno; T Sato
Journal:  J Hepatol       Date:  1993-04       Impact factor: 25.083

3.  The origin of monomeric and polymeric forms of IgA in man.

Authors:  J Radl; H R Schuit; J Mestecky; W Hijmans
Journal:  Adv Exp Med Biol       Date:  1974       Impact factor: 2.622

4.  Serum immunoglobulins, complement component levels and autoantibodies in liver disease.

Authors:  R A Thompson; R Carter; R P Stokes; A M Geddes; J A Goodall
Journal:  Clin Exp Immunol       Date:  1973-07       Impact factor: 4.330

5.  Mesenteric lymph as a major source of serum IgA in guinea pigs and rats.

Authors:  J P Vaerman; C André; H Bazin; J F Heremans
Journal:  Eur J Immunol       Date:  1973-09       Impact factor: 5.532

6.  Virus-specific polymeric immunoglobulin A antibodies in serum from patients with rubella, measles, varicella, and herpes zoster virus infections.

Authors:  A Negro Ponzi; C Merlino; A Angeretti; R Penna
Journal:  J Clin Microbiol       Date:  1985-10       Impact factor: 5.948

7.  Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis.

Authors:  H J Alter; R H Purcell; J W Shih; J C Melpolder; M Houghton; Q L Choo; G Kuo
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

8.  Evaluation of three hepatitis C virus-related antibodies C100, KCL-163, JCC. Tests for screening blood donors.

Authors:  S Fujiyama; S Kawano; S Sato; T Sato; T Kawahara; K Mizuno; Y Kusumoto; M Esumi; T Shikata
Journal:  Dig Dis Sci       Date:  1992-10       Impact factor: 3.199

9.  Use of conserved sequences from hepatitis C virus for the detection of viral RNA in infected sera by polymerase chain reaction.

Authors:  G Inchauspe; K Abe; S Zebedee; M Nasoff; A M Prince
Journal:  Hepatology       Date:  1991-10       Impact factor: 17.425

10.  Clinical evaluation of three anti-HCV ELISAs in patients with various liver diseases.

Authors:  S Kawano; S Fujiyama; S Sato; M Tanaka; M Goto; Y Taura; T Sato; T Kawahara; K Mizuno; S Nonaka
Journal:  Dig Dis Sci       Date:  1992-08       Impact factor: 3.199

View more
  4 in total

1.  Clinical study of IgA antibody against hepatitis C virus core antigen in patients with type C chronic liver disease.

Authors:  M Tanaka; S Sato; S Fujiyama; S Kawano; Y Taura; H Chikazawa; Y Honda; J Shibata; T Sato
Journal:  Dig Dis Sci       Date:  1995-02       Impact factor: 3.199

2.  Genetic variants of the IgA Fc receptor (FcalphaR, CD89) promoter in chronic hepatitis C patients.

Authors:  Azuma Watanabe; Toshibumi Shimokawa; Mitsuhiko Moriyama; Fumihiko Komine; Shuichi Amaki; Yasuyuki Arakawa; Chisei Ra
Journal:  Immunogenetics       Date:  2006-10-11       Impact factor: 2.846

3.  Simultaneous detection of immunoglobulin A (IgA) and IgM antibodies against hepatitis E virus (HEV) Is highly specific for diagnosis of acute HEV infection.

Authors:  Masaharu Takahashi; Shigeyuki Kusakai; Hitoshi Mizuo; Kazuyuki Suzuki; Kuniko Fujimura; Kazuo Masuko; Yoshiki Sugai; Tatsuya Aikawa; Tsutomu Nishizawa; Hiroaki Okamoto
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

4.  Envelope-Specific IgG3 and IgG1 Responses Are Associated with Clearance of Acute Hepatitis C Virus Infection.

Authors:  Melanie R Walker; Auda A Eltahla; Michael M Mina; Hui Li; Andrew R Lloyd; Rowena A Bull
Journal:  Viruses       Date:  2020-01-08       Impact factor: 5.048

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.